What is William Blair's Forecast for Biogen Q2 Earnings?

Key Points

• William Blair has revised down its Q2 2026 earnings per share (EPS) estimate for Biogen to $4.57, slightly below its previous estimate of $4.60.
• Biogen's latest quarterly earnings report exceeded expectations, with EPS of $5.47, beating consensus estimates by $1.54 and showing a 7.3% revenue increase year-over-year.
• Analysts have mixed opinions on Biogen, with 21 analysts rating the stock as a hold and others offering target prices ranging from $115 to $219.

Biogen Inc. (NASDAQ:BIIB - Free Report) - Stock analysts at William Blair decreased their Q2 2026 earnings estimates for shares of Biogen in a research report issued to clients and investors on Thursday, July 31st. William Blair analyst M. Minter now forecasts that the biotechnology company will earn $4.57 per share for the quarter, down from their previous estimate of $4.60. The consensus estimate for Biogen's current full-year earnings is $15.83 per share. William Blair also issued estimates for Biogen's Q3 2026 earnings at $3.07 EPS, FY2026 earnings at $15.14 EPS and FY2029 earnings at $18.90 EPS.

Biogen (NASDAQ:BIIB - Get Free Report) last released its quarterly earnings data on Thursday, July 31st. The biotechnology company reported $5.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.93 by $1.54. The firm had revenue of $2.65 billion during the quarter, compared to analysts' expectations of $2.32 billion. Biogen had a net margin of 15.31% and a return on equity of 13.85%. Biogen's revenue was up 7.3% compared to the same quarter last year. During the same period last year, the business earned $5.28 earnings per share.

Other research analysts have also issued reports about the company. Royal Bank Of Canada raised their price target on Biogen from $208.00 to $219.00 and gave the stock an "outperform" rating in a research report on Friday, August 1st. HC Wainwright boosted their price target on shares of Biogen from $187.00 to $194.00 and gave the stock a "buy" rating in a research note on Friday, August 1st. Oppenheimer set a $205.00 price objective on shares of Biogen in a research note on Friday, May 2nd. Needham & Company LLC reissued a "hold" rating on shares of Biogen in a research report on Thursday, June 12th. Finally, Citigroup lifted their target price on Biogen from $125.00 to $135.00 and gave the company a "neutral" rating in a report on Friday, August 1st. Twenty-one analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus target price of $185.63.

Biogen Trading Down 2.7%

NASDAQ:BIIB traded down $3.55 on Monday, reaching $129.34. The company's stock had a trading volume of 1,537,894 shares, compared to its average volume of 1,573,155. The firm has a market cap of $18.96 billion, a price-to-earnings ratio of 12.37, a price-to-earnings-growth ratio of 1.04 and a beta of 0.13. The company has a quick ratio of 1.79, a current ratio of 2.50 and a debt-to-equity ratio of 0.36. Biogen has a 12-month low of $110.04 and a 12-month high of $207.59. The stock has a 50 day moving average price of $130.06 and a 200 day moving average price of $131.64.

Institutional Trading of Biogen

Institutional investors have recently modified their holdings of the business. Opal Wealth Advisors LLC acquired a new position in shares of Biogen during the 1st quarter worth $26,000. Vision Financial Markets LLC purchased a new position in Biogen in the first quarter valued at about $27,000. Greykasell Wealth Strategies Inc. acquired a new stake in shares of Biogen during the 1st quarter valued at approximately $27,000. Colonial Trust Co SC grew its holdings in shares of Biogen by 9,300.0% in the 4th quarter. Colonial Trust Co SC now owns 188 shares of the biotechnology company's stock worth $29,000 after acquiring an additional 186 shares during the period. Finally, Zions Bancorporation National Association UT acquired a new position in Biogen during the first quarter worth $29,000. 87.93% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In related news, insider Rachid Izzar sold 2,223 shares of the firm's stock in a transaction dated Tuesday, July 8th. The shares were sold at an average price of $135.00, for a total value of $300,105.00. Following the completion of the sale, the insider owned 6,330 shares in the company, valued at $854,550. This trade represents a 25.99% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.18% of the stock is currently owned by company insiders.

Biogen Company Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.